Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection
NCT ID: NCT02510872
Last Updated: 2015-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
19 participants
INTERVENTIONAL
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The locoregional recurrence rate is indeed high (up 40%) over the first two years of this therapeutic method.
The conventional imaging methods such as CT and MRI appear limited in terms of sensitivity because of the many post-treatment changes are fibrosis, tissue edema and the tissue distortion.
PET-CT 18F-FDG proves to be a non-invasive, reliable for the detection of residual tumor and metastasis, even in the absence of clinical signs.
To date, the acquired CT examination in the same time and in the same position that PET is performed without iodinated contrast injection, used for anatomical identification and attenuation correction of PET fused images. The patient usually has a second CT imaging, centered on the neck with contrast injection iodized within the radiology department.
To date, no team has yet studied the interest of the PET-CT 18F-FDG coupled with a CT scan with contrast injection iodized in the diagnosis of early recurrence in head and neck malignancies while interest of the contrast agent injection has been demonstrated in ovarian neoplastic recurrence research, pancreatic and colon.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC
NCT04196985
Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma
NCT02515084
Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma
NCT01827709
Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma
NCT00634777
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
NCT06914999
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-FDG PET combined with CT with iodinated contrast injection
18F-FDG PET combined with CT with iodinated contrast injection
18F-FDG PET combined with CT with iodinated contrast injection
18F-FDG PET combined with CT without injection
18F-FDG PET combined with CT without injection
18F-FDG PET combined with CT without injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-FDG PET combined with CT with iodinated contrast injection
18F-FDG PET combined with CT without injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Squamous cell carcinoma of head and neck
* neoplastic Location: oropharynx, oral cavity, hypopharynx, larynx
* New Patients treated with concomitant radiochemotherapy
* Treatment with chemoradiotherapy ended 3 months ago
* Affiliation to a social security scheme
* Patient who provided written informed consent
Exclusion Criteria
* Breastfeeding
* Creation of a cervical CT with injection of iodinated contrast, in the therapeutic monitoring, dated less than 14 days
* Other history of malignancy, including head and neck carcinomas previously treated outside the basal cell cancer or cervical cancer, treated and cured
* uncontrolled Infectious diseases
* Allergy to iodine
* Severe renal impairment (renal clearance \<30ml / min according to Cockcroft)
* No consent
* Patient deprived of liberty, under guardianship
* Any medical or psychological condition associated that might compromise the patient's ability to participate in the study
* Failure to submit to medical monitoring study for geographical, social or psychic
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service Médecine Nucléaire
Caen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-160
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.